P&G, National Breast Cancer Foundation team up to fight breast cancer
CINCINNATI — Procter & Gamble Company and the National Breast Cancer Foundation have kicked off the fifth annual Give Hope program and its “Do It For the Girls!” campaign designed to rally women to take control of their breast health, take action and create an early detection plan in the fight against breast cancer.
One-in-8 women will get breast cancer in her lifetime, but if detected in the early (localized) stage, the five-year survival rate is 98%. Routine breast self-exams and a predetermined early detection plan are the most powerful tools in the fight against breast cancer, and save thousands of lives every year.
Campaign representative and breast cancer survivor Giuliana Rancic, along with P&G employee survivors, will lead the "Do It For the Girls!” Day of Action on Sept. 20 via a Twitter party, #GiveHope, designed to motivate women to conduct a breast self-exam this day, and take the first steps toward implementing an early detection plan.
“The early detection message is vitally important to me, and one that I need all women to hear and act upon, especially since it saved my life,” Rancic stated. “There are no second chances with breast cancer — and one of every eight of us are going to get it. The most critical recourse to surviving the disease is to catch it before it spreads, and the only way to catch it early is to be proactive about managing our breast health.”
Women are strongly encouraged to participate in the "Do It For the Girls!" Day of Action by joining the Twitter party, conducting a breast self-exam and spreading the word with friends and family on Facebook. Participants can create a symbol of their commitment to breast cancer early detection through a custom photo app found at Facebook.com/pgmygive. The goal is to create enough social momentum for this early detection call-to-action, that the message not only reaches women nationwide, but motivates them to take action. P&G also is incentivizing participation by donating $1 to the NBCF for every profile picture created, up to $25,000.
Consumers also can participate in the program by redeeming coupons from the Sept. 30 and Oct. 14 P&G BrandSaver found in Sunday papers across the nation with discounts for P&G products including, but not limited to, Always, Clairol, Cover Girl, Crest and Olay.
For each BrandSaver coupon redeemed, P&G will donate 2 cents and 1 cent, respectively, (uncapped) to the NBCF. Since 2008, P&G has raised $1.9 million for the NBCF through this effort. The funds support the NBCF’s mission to save lives through early detection education and to provide mammograms for those in need.
Dulcolax, Colon Cancer Alliance raises $120,000 in Philadelphia Undy 5000 5K Run/Walk
PHILADELPHIA — The Undy 5000 5K Run/Walk, presented by Dulcolax, returned here for the fifth consecutive year to help raise funds for colon cancer research. Almost 1,000 participants ran in their underwear as a tongue-in-cheek reference to the area affected by colon cancer, raising $120,000 for Colon Cancer community programs.
The Philadelphia Undy 5000 featured the Colon Cancer Alliance’s Inflatable Colon; a giant, walk-through colon that shows the various stages of colon cancer, including descriptions about Crohn’s disease and Colitis.
The Undy 5000 will be held in 16 cities across the country this year to educate the public about colon cancer, promote screenings and encourage people to talk about the disease. Instead of raceday T-shirts, all registered participants receive a commemorative pair of Undy 5000 boxers. It is a family-friendly event open to all ages, and in addition to the 5K, there is a 1-mile fun run. CCA hosts the event.
Shop Rite stores joined Boehringer-Ingelheim, which owns the Dulcolax brand, and the CCA to promote the race and raise awareness around colon cancer. Shop Rite also offered specially marked Dulcolax boxes, containing information about the importance of getting screened for colon cancer.
J&J seeks FDA approval for intravenous Simponi
HORSHAM, Pa. — A subsidiary of Johnson & Johnson is hoping to gain Food and Drug Administration approval for a new formulation of one of its drugs.
Janssen Biotech announced that it had filed an application with the FDA seeking approval for an intravenous formulation of Simponi (golimumab) in adults with moderately to severely active rheumatoid arthritis, which affects an estimated 1.5 million Americans.
The FDA approved the subcutaneously injected formulation of Simponi in April 2009 for moderately to severely active rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis.